Resveratrol Ameliorates Diabetes-Induced Cardiac Dysfunction Through AT1R-ERK/p38 MAPK Signaling Pathway

Cardiovascular Toxicology

Volumn 16, Issue 2, 2016, Pages 130-137

  Gao, Yonglin ^a   Kang, Le ^a   Li, Chunmei ^a   Wang, Xiaoyan ^a   Sun, Chengfeng ^a   Li, Qingzhong ^a   Liu, Ruihua ^b   Wang, Jianping ^b  

^a YANTAI UNIVERSITY   (China)

^b YANTAI YUHUANGDING HOSPITAL   (China)

Author keywords

AT1R ERK p38 MAPK; Diabetes induced cardiac dysfunction; Glucose and lipid metabolism; Inflammation response; Resveratrol

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; RESVERATROL; STREPTOZOCIN; TUMOR NECROSIS FACTOR ALPHA; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETES MELLITUS; ENZYME PHOSPHORYLATION; GLUCOSE METABOLISM; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE FIBROSIS; HEART PROTECTION; LEFT VENTRICULAR SYSTOLIC PRESSURE; LIPID METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; HEART DISEASES; METABOLISM; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; HEART DISEASES; MALE; MAP KINASE SIGNALING SYSTEM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; STILBENES;

EID: 84961119684     PISSN: 15307905     EISSN: 15590259     Source Type: Journal    
DOI: 10.1007/s12012-015-9321-3     Document Type: Article

References (31)

1. Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004). Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care,27, 1047–1053.
2. Bell, D. S. (2003). Heart failure: The frequent, forgotten, and often fatal complication of diabetes. Diabetes Care,26, 2433–2441.
3. Boudina, S., & Abel, E. D. (2007). Diabetic cardiomyopathy revisited. Circulation,115, 3213–3223.
4. Chang, S. H., Liu, C. J., Kuo, C. H., Chen, H., Lin, W. Y., Teng, K. Y., et al. (2011). Garlic oil alleviates MAPKs- and IL-6-mediated diabetes-related cardiac hypertrophy in STZ-induced DM rats. Evidence-Based Complementary and Alternative Medicine,2011, 950150.
5. Gava, E., Samad-Zadeh, A., Zimpelmann, J., Bahramifarid, N., Kitten, G. T., Santos, R. A., et al. (2009). Angiotensin-(1–7) activates a tyrosine phosphatase and inhibits glucose-induced signalling in proximal tubular cells. Nephrology, Dialysis, Transplantation,24, 1766–1773.
6. Borriello, A., Cucciolla, V., Della Ragione, F., & Galletti, P. (2010). Dietary polyphenols: Focus on resveratrol, a promising agent in the prevention of cardiovascular diseases and control of glucose homeostasis. Nutrition, Metabolism and Cardiovascular Diseases,20, 618–625.
7. Liu, K., Zhou, R., Wang, B., & Mi, M. T. (2014). Effect of resveratrol on glucose control and insulin sensitivity: A meta-analysis of 11 randomized controlled trials. American Journal of Clinical Nutrition,99, 1510–1519.
8. Tomé-Carneiro, J., Gonzálvez, M., Larrosa, M., Yáñez-Gascón, M. J., García-Almagro, F. J., Ruiz-Ros, J. A., et al. (2012). One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. American Journal of Cardiology,110, 356–363.
9. Olson, E. R., Naugle, J. E., Zhang, X., Bomser, J. A., & Meszaros, J. G. (2005). Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol. American Journal of Physiology Heart and Circulatory Physiology,288, H1131–H1138.
10. Bidasee, K. R., Zhang, Y., Shao, C. H., Wang, M., Patel, K. P., Dincer, U. D., & Besch, H. R, Jr. (2004). Diabetes increases formation of advanced glycation end products on Sarco(endo) plasmic reticulum Ca2+-ATPase. Diabetes,53, 463–473.
11. Li, C., Gao, Y., Tian, J., Xing, Y., Zhu, H., & Shen, J. (2012). Long-term oral Asperosaponin VI attenuates cardiac dysfunction, myocardial fibrosis in a rat model of chronic myocardial infarction. Food and Chemical Toxicology,50, 1432–1438.
12. Venkatachalam, K., Mummidi, S., Cortez, D. M., Prabhu, S. D., Valente, A. J., & Chandrasekar, B. (2008). Resveratrol inhibits high glucose-induced PI3K/Akt/ERK-dependent interleukin-17 expression in primary mouse cardiac fibroblasts. American Journal of Physiology Heart and Circulatory Physiology,294(5), H2078–H2087.
13. Novaes, R. D., Peluzio, Mdo C., & Maldonado, I. R. (2012). Resveratrol causes antiatherogenic effects in an animal model of atherosclerosis. Arquivos Brasileiros de Cardiologia,98(6), 571.
14. Göçmen, A. Y., Burgucu, D., Karadoğan, I., Timurağaoğlu, A., & Gümüşlü, S. (2013). The effect of trans-resveratrol on platelet-neutrophil complex formation and neutrophil burst in hypercholesterolemic rats. Experimental & Clinical Cardiology,18(2), e111–e114.
15. Farb, M. G., Bigornia, S., Mott, M., Tanriverdi, K., Morin, K. M., Freedman, J. E., et al. (2011). Reduced adipose tissue inflammation represents an intermediate cardiometabolic phenotype in obesity. Journal of the American College of Cardiology,58, 232–237.
16. Movahed, A., Nabipour, I., Lieben, L. X., Thandapilly, S. J., Yu, L., Kalantarhormozi, M., et al. (2013). Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evidence-Based Complementary and Alternative Medicine,2013, 851267.
17. Adeghate, E., Kalasz, H., Veress, G., & Teke, K. (2010). Medicinal chemistry of drugs used in diabetic cardiomyopathy. Current Medicinal Chemistry,17, 517–551.
18. Luo, B., Li, B., Wang, W., Liu, X., Xia, Y., Zhang, C., et al. (2014). An FNLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS One,9(8), e104771.
19. Cong, X., Li, Y., Lu, N., Dai, Y., Zhang, H., Zhao, X., & Liu, Y. (2014). Resveratrol attenuates the inflammatory reaction induced by ischemia/reperfusion in the rat heart. Molecular Medicine Reports,9, 2528–2532.
20. Thomas, C. M., Yong, Q. C., Seqqat, R., Chandel, N., Feldman, D. L., Baker, K. M., & Kumar, R. (2013). Direct renin inhibition prevents cardiac dysfunction in a diabetic mouse model: Comparison with an angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor. Clinical Science (Lond),124, 529–541.
21. Yong, Q. C., Thomas, C. M., Seqqat, R., Chandel, N., Baker, K. M., & Kumar, R. (2013). Angiotensin type 1a receptor-deficient mice develop diabetes-induced cardiac dysfunction, which is prevented by renin-angiotensin system inhibitors. Cardiovascular Diabetol,12, 169.
22. Rosenkranz, S. (2004). TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovascular Research,63, 423–432.
23. Sugden, P. H., & Clerk, A. (1998). Stress-responsive mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circulation Research,83, 345–352.
24. Tibbles, L. A., & Woodgett, J. R. (1999). The stress-activated protein kinase pathways. Cellular and Molecular Life Sciences,55, 1230–1254.
25. Lakshmanan, A. P., Harima, M., Sukumaran, V., Soetikno, V., Thandavarayan, R. A., Suzuki, K., et al. (2012). Modulation of AT-1R/AMPK-MAPK cascade plays crucial role for the pathogenesis of diabetic cardiomyopathy in transgenic type 2 diabetic (Spontaneous Diabetic Torii) rats. Biochemical Pharmacology,83, 653–660.
26. Erdogan, D., Yucel, H., Uysal, B. A., Ersoy, I. H., Icli, A., Akcay, S., et al. (2013). Effects of prediabetes and diabetes on left ventricular and coronary microvascular functions. Metabolism,62, 1123–1130.
27. Li, J., Peng, L., Du, H., Wang, Y., Lu, B., Xu, Y., et al. (2014). The protective effect of beraprost sodium on diabetic cardiomyopathy through the inhibition of the p38 MAPK signaling pathway in high-fat-induced SD rats. International Journal of Endocrinology,2014, 901437.
28. Xu, H., Xiong, C., He, L., Wu, B., Peng, L., Cheng, Y., et al. (2013). Trans- resveratrol attenuates high fatty acid-induced P2X7 receptor expression and IL-6 release in PC12 cells: Possible role of P38 MAPK pathway. Inflammation,94, 63–70.
29. Miyazaki, R., Ichiki, T., Hashimoto, T., Inanaga, K., Imayama, I., Sadoshima, J., & Sunagawa, K. (2008). SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells. Arteriosclerosis, Thrombosis, and Vascular Biology,28, 1263–1269.
30. Biala, A., Tauriainen, E., Siltanen, A., Shi, J., Merasto, S., Louhelainen, M., et al. (2010). Resveratrol induces mitochondrial biogenesis and ameliorates Ang II-induced cardiac remodeling in transgenic rats harboring human renin and angiotensinogen genes. Blood Pressure,19, 196–205.
31. Chen, T., Li, J., Liu, J., Li, N., Wang, S., Liu, H., et al. (2014). Activation of SIRT3 by resveratrol ameliorates cardiac fibrosis and improves cardiac function via TGF-β/Smad3 pathway. American Journal of Physiology Heart and Circulatory Physiology. doi:10.1152/ajpheart.00454.2014.